PMDA drug package insert
デポ・メドロール水懸注20mg
PMDA Prescription drug · ファイザー株式会社 · package insert Mar 17, 2026
Key facts
| Brand names | デポ・メドロール水懸注20mg, デポ・メドロール水懸注40mg |
|---|---|
| Nonproprietary names | メチルプレドニゾロン酢酸エステル |
| Companies | 製造販売元／ファイザー株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 持続性合成副腎皮質ホルモン剤 |
| Therapeutic category codes | 872456 |
| YJ codes | 2456402C1044, 2456402C2040 |
| Approval numbers | 22000AMX00385, 22000AMX00715 |
| Package insert edition | 第6版 |
| Package insert date | Mar 17, 2026 |
| PMDA document key | 672212_2456402C1044_3 |
| PMDA company code | 672212 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: